舌下含服粉尘螨滴剂治疗不同严重程度变应性鼻炎患者的疗效分析

胡晓勋; 刘季萍; 付书彩; 韦永豪; 胡伟; 刘雅凌; 游锦; 张敏

doi:10.13201/j.issn.1001-1781.2015.03.008

舌下含服粉尘螨滴剂治疗不同严重程度变应性鼻炎患者的疗效分析

- 江西九江学院附属医院耳鼻咽喉头颈外科(江西九江, 332000)

详细信息

通讯作者: 胡晓勋,E-mail:happyxuanhu@163.com

中图分类号: R765.21

收稿日期: 2014-09-01

Efficacy of sublingual immunotherapy with Dermatophagoides farinae drops on patients with allergic rhinitis of different symptom severity

- Department of Otorhinolaryngology Head and Neck Surgery, Jiujiang University Hospital, Jiujiang, 332000, China

More Information

Corresponding author: HU Xiaoxun, E-mail: happyxuanhu@163.com

Received Date: 01 September 2014

摘要

摘要: 目的:探讨舌下含服粉尘螨滴剂治疗不同严重程度变应性鼻炎(AR)患者的疗效。方法:143例AR患者接受舌下特异性免疫治疗(SLIT)治疗1.5~2.0年,按疾病症状的严重程度不同分为中度组62例和重度组81例,评估不同严重程度AR患者在SLIT治疗前、治疗半年、1年及1.5~2.0年时的鼻部症状评分(TNSS)、药物评分(TMS)和体征评分变化。结果:与治疗前相比,SLIT治疗半年、1年、1.5~2.0年后,不同严重程度组AR患者的TNSS、TMS以及体征评分均显著改善(P<0.05);SLIT治疗前,重度组的TNSS和体征评分均显著高于中度组(Z=10.40、2.40,P<0.05),而用药评分差异无统计学意义(Z值为0.00,P>0.05);在治疗半年后,中度组与重度组之间的体征评分差异有统计学意义(Z=3.32,P<0.05),而TNSS和TMS差异无统计学意义(Z=1.58、0.37,P>0.05)。在治疗1年及1.5~2.0年,中度组与重度组之间的TNSS、TMS以及体征评分差异均无统计学意义(P>0.05)。结论:舌下含服粉尘螨滴剂对AR具有显著疗效,中度和重度AR患者最终都取得了相近的疗效。
- 舌下特异性免疫治疗 /
- 鼻炎 /
- 变应性 /
- 疗效
Abstract: Objective: To evaluate the efficacy of sublingual immunotherapy (SLIT) with Dermatophagoides farinae drops for allergic rhinitis (AR) of different symptom severity.Method: This retrospective analysis to receive SLIT treatment of 143 cases of patients with allergic rhinitis, according to the severity of disease symptoms divided into two groups, moderate group (62 patients) and severe group (81 patients). Before SLIT and after SLIT for half year, 1 year and 1.5-2.0 years, the TNSS, TMS and sign scores of patients with allergic rhinitis were evaluated.Result: The TNSS, TMS and sign scores had continuously improved significantly after SLIT for half year, 1 year and 1.5-2.0 years in two groups as compared with baseline (P<0.05). Before SLIT, TNSS and sign scores of severe group had a significantly higher level than moderate group (Z=10.40, 2.40, P<0.05), while TMS of two groups had no significant differences (Z=0.00, P>0.05). Half year after SLIT treatment, in two groups for sign scores, there were significant differences (Z=3.32, P<0.05), and there were no significant differences for TNSS (Z=1.58,P>0.05) and TMS (Z=0.37, P>0.05). 1 and 1.5-2.0 years after SLIT, there were no significant differences in two groups for TNSS, TMS and sign scores (P>0.05).Conclusion: SLIT with Dermatophagoides farinae drops for 1.5-2.0 years is effective in the patients with allergic rhinitis of different symptom severity. And equivalent efficacy could be achieved for different symptom severity.
- sublingual immunotherapy /
- rhinitis /
- allergic /
- efficacy

HTML全文

参考文献(15)

[1]	HAN D H,RHEE C S. Sublingual immunotherapy in allergic rhinitis[J]. Asia Pac Allergy, 2011, 1:123-129.
[2]	LA ROSA M, LIONETTI E, LEONARDI S, et al. Specific immunotherapy in children:the evidence[J]. Int J Immunopathol Pharmacol, 2011, 24(4 Suppl):69-78.
[3]	BOUSQUET J, KHALTAEV N, CRUZ A A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)[J]. Allergy, 2008, 63 Suppl 86:8-160.
[4]	中华耳鼻咽喉头颈外科杂志编辑委员会, 中华医学会耳鼻咽喉科分会. 变应性鼻炎的诊治原则和推荐方案(2004年, 兰州)[J]. 中华耳鼻咽喉头颈外科杂志, 2005, 40(3):166-167.
[5]	中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 变应性鼻炎免疫治疗专家共识[J]. 中华耳鼻咽喉头颈外科杂志, 2011, 46(13):976-980.
[6]	FUJITA H, SOYKA M B, AKDIS M, et al. Mechanisms of allergen-specific immunotherapy[J]. Clin Transl Allergy, 2012, 2:2-2.
[7]	SMARR C B, BRYCE P J, MILLER S D. Antigen-specific tolerance in immunotherapy of th2-associated allergic diseases[J]. Crit Rev Immunol, 2013, 33:389-414.
[8]	WILSON D R, LIMA M T, DURHAM S R. Sublingual immunotherapy for allergic rhinitis:systematic review and meta-analysis[J]. Allergy, 2005, 60:4-12.
[9]	EIFAN A O, CALDERON M A, DURHAM S R. Allergen immunotherapy for house dust mite:clinical efficacy and immunological mechanisms in allergic rhinitis and asthma[J]. Expert Opin Biol Ther, 2013, 13:1543-1556.
[10]	CALAMITA Z, SACONATO H, PELA A B, et al. Efficacy of sublingual immunotherapy in asthma:systematic review of randomized-clinical trials using the Cochrane Collaboration method[J]. Allergy, 2006, 61:1162-1172.
[11]	JACOBSEN L, NIGGEMANN B, DREBORG S, el al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma:10-year follow-up on the PAT study[J]. Allergy, 2007, 62:943-948.
[12]	李添应, 陈德华, 林志斌, 等. 舌下含服粉尘螨滴剂治疗变应性鼻炎的疗效观察[J]. 中华耳鼻咽喉头颈外科杂志, 2011, 46(11):859-862.
[13]	朱亮, 朱鲁平, 陈若希,等. 皮下免疫和舌下免疫治疗尘螨变应性鼻炎的疗效分析[J]. 中华耳鼻咽喉头颈外科杂志, 2011,46(13):986-991.
[14]	杜晓东, 舒畅, 徐桂容,等. 舌下含服粉尘螨滴剂治疗变应性鼻炎疗效观察[J]. 临床耳鼻咽喉头颈外科杂志, 2012, 26(8):372-373.
[15]	HOWARTH P, MALLING H J, MOLIMARD P D. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients[J]. Allergy, 2012, 67:321-327.